Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
- PMID: 23361908
- PMCID: PMC3612864
- DOI: 10.1182/blood-2012-08-453860
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
Abstract
Older patients are increasingly undergoing allogeneic hematopoietic transplantation. A relevant question is whether outcomes can be improved with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD). Accordingly, transplants in leukemia/lymphoma patients age ≥50 years were analyzed comparing outcomes for recipients of MSD ≥50 (n = 1415) versus MUD <50 years (n = 757). Risks of acute graft-versus-host disease (GVHD) grade 2 to 4 (hazard ratio [HR], 1.63; P < .001), 3 to 4 (HR, 1.85; P < .001), and chronic GVHD (HR, 1.48; P < .0001) were higher after MUD compared with MSD transplants. The effect of donor type on nonrelapse mortality (NRM), relapse, and overall mortality was associated with performance score. For patients with scores of 90 or 100, NRM (HR, 1.42; P = .001), relapse (HR, 1.45; P < .001), and overall mortality (HR, 1.28; P = .001) risks were higher after MUD transplants. For patients with scores below 90, NRM (HR, 0.96; P = .76), relapse (HR, 0.86; P = .25), and overall mortality (HR, 0.90; P = .29) were not significantly different after MUD and MSD transplants. These data favor an MSD over a MUD in patients age ≥50 years.
Figures

Similar articles
-
Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome.Transplant Cell Ther. 2023 Nov;29(11):697.e1-697.e10. doi: 10.1016/j.jtct.2023.08.009. Epub 2023 Aug 12. Transplant Cell Ther. 2023. PMID: 37579919
-
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.JAMA Oncol. 2022 Mar 1;8(3):404-411. doi: 10.1001/jamaoncol.2021.6846. JAMA Oncol. 2022. PMID: 35024768 Free PMC article.
-
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7. J Hematol Oncol. 2021. PMID: 33794963 Free PMC article.
-
Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.Hematol Oncol. 2023 Feb;41(1):147-158. doi: 10.1002/hon.3094. Epub 2022 Oct 31. Hematol Oncol. 2023. PMID: 36268564
-
Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.Hematology. 2020 Dec;25(1):356-365. doi: 10.1080/16078454.2020.1831292. Hematology. 2020. PMID: 33054609
Cited by
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.Blood Cancer J. 2022 Sep 28;12(9):140. doi: 10.1038/s41408-022-00729-y. Blood Cancer J. 2022. PMID: 36167679 Free PMC article.
-
Sixty as the new forty: considerations on older related stem cell donors.Bone Marrow Transplant. 2017 Jan;52(1):15-19. doi: 10.1038/bmt.2016.201. Epub 2016 Aug 8. Bone Marrow Transplant. 2017. PMID: 27500950 Review.
-
Hematology 2022-what is complete HLA match in 2022?Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):83-89. doi: 10.1182/hematology.2022000326. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485162 Free PMC article.
-
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.Am J Hematol. 2023 Apr;98(4):608-619. doi: 10.1002/ajh.26834. Epub 2023 Jan 16. Am J Hematol. 2023. PMID: 36606713 Free PMC article.
-
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther. 2023 Oct;29(10):611-618. doi: 10.1016/j.jtct.2023.07.015. Epub 2023 Jul 21. Transplant Cell Ther. 2023. PMID: 37481243 Free PMC article.
References
-
- Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. http://www.cibmtr.org.
-
- Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25):1794–1800. - PubMed
-
- Liu QF, Xu XJ, Chen YK, et al. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann Hematol. 2011;90(3):331–341. - PubMed
-
- Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007;13(5):601–607. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials